Search clinical trials for: Antineoplastic Agents

Total 188068 results

Assiut University

Unknown

Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide

Ovarian Failure
Novartis Pharmaceuticals

Completed

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Acromegaly

Spain
Oncoscience AG
University of Kiel; Marienhospital Herne; Gemeinschaftspraxis für Hämatologie... and other collaborators

Completed

Nimotuzumab in Adults With Pancreatic Cancer

Pancreatic Cancer, Advanced or Metastatic

Germany
Sandoz

Completed

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

HIV Infections | Diarrhea

United States
Lucia Del Mastro,MD

Completed

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

HER-2 Positive Breast Cancer

Italy
Amsterdam UMC, location VUmc
Amgen

Completed

Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer (Vectibix)

Pancreatic Cancer

Netherlands
Institut National de la Santé Et de la Recherche...

Completed

Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide (FIBROSAND)

Idiopathic Pulmonary Fibrosis
Maastricht Radiation Oncology
Merck Sharp & Dohme LLC; Academisch Ziekenhuis Maastricht

Completed

Phase I Cetuximab and Concurrent Radio-chemotherapy

Non-small Cell Lung Cancer

Netherlands
National Center for Research Resources (NCRR)
Yale University

Completed

Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia

Hereditary Hemorrhagic Telangiectasia | Ectasia
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (ALL2418)

Acute Lymphoid Leukemia

Italy
University Medical Center Groningen

Recruiting

Investigating Cardiovascular Adverse Events Related to Cancer Treatment (InvestiCAT)

Toxicity Due to Chemotherapy | Cancer, Treatment-Related | Cardiovascular Morbidity

Netherlands
Pfizer

Completed

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, Spain, France, Switzerland, United Kingdom, Belgium, Germany
Fondazione Italiana Linfomi ONLUS

Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (FIL_BRB)

Waldenstrom's Macroglobulinemia

Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

Lymphoma, B-Cell
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Lymphoproliferative Disorder

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia
China Medical University, China

Not yet recruiting

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Colorectal Adenocarcinoma | Gastric

China
Fudan University

Not yet recruiting

Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Colorectal Cancer Liver Metastases

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

Pancreatic Neoplasms

China
Novartis Pharmaceuticals

Recruiting

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B-cell Lymphoma

Brazil
Yonsei University

Not yet recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Non Small Cell Lung Cancer

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
University of Kansas Medical Center

Recruiting

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Advanced Biliary Tract Cancer

United States
Shi Yuankai

Recruiting

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Head and Neck Squamous Cell Carcinoma

China
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Medidata Solutions

Recruiting

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
Assistance Publique - Hôpitaux de Paris

Recruiting

Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma (KAPVEC)

Kaposi Sarcoma

France
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Recruiting

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Yonsei University

Not yet recruiting

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Metastatic Breast Cancer

Korea, Republic of
Sichuan University
Geneplus-Beijing Co. Ltd.

Recruiting

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Non-small Cell Lung Cancer

China
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria
Fudan University

Terminated

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Non-small Cell Lung Cancer

China
AstraZeneca

Active, not recruiting

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE)

Melanoma

France, Germany, Italy, Spain, Belgium, Canada, Poland, Korea, Republic of, United Kingdom, United States, Australia
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
AstraZeneca

Completed

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom (CODAK)

Non-Small Cell Lung Cancer NSCLC

United Kingdom
University of Aarhus
Genzyme, a Sanofi Company

Completed

Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

Multiple Sclerosis

Denmark
Canadian Cancer Trials Group
Pfizer

Completed

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

Metastatic Colorectal Cancer

Canada
Genmab

Terminated

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Head and Neck Cancer | Squamous Cell Carcinoma

United Kingdom, Belgium, France
Chinese University of Hong Kong

Completed

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Acral Lentiginous Melanoma

Hong Kong
Simon C Pacey, MD
AstraZeneca

Active, not recruiting

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab (CALIBRATION)

Oesophageal Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Cedars-Sinai Medical Center

Completed

Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

Breast Cancer | Metastatic Triple Negative

United States
Celltrion
Nippon Kayaku Co., Ltd.

Completed

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

HER2-positive Carcinoma of Breast

Italy, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
University of Alabama at Birmingham
Merck Sharp & Dohme LLC

Terminated

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Penile Squamous Cell Carcinoma

United States
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of
Fundación GECP

Completed

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. (S-REAL)

Small Cell Lung Cancer (SCLC)

Spain
Hellenic GenitoUrinary Cancer Group

Active, not recruiting

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Bladder Cancer

Greece
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC; National Institute for Health Research Biomedical...

Active, not recruiting

A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients (c-TRAK-TN)

Triple Negative Breast Cancer

United Kingdom
Five Prime Therapeutics, Inc.

Completed

FPA150 in Patients With Advanced Solid Tumors (FPA150-001)

Breast Cancer | Ovarian Cancer | Advanced Solid Tumors | Endometrial Cancer

United States, Korea, Republic of
Five Prime Therapeutics, Inc.

No longer available

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer (FPA144)

Recurrent Bladder Cancer
Takayuki Yoshino
Sumitomo Pharma Co., Ltd.

Terminated

Special Combination of BBI608 and Pembrolizumab

Metastatic Colorectal Cancer

Japan

Search clinical trials for: Antineoplastic Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations